InvestorsHub Logo
Followers 85
Posts 5198
Boards Moderated 1
Alias Born 01/23/2010

Re: None

Saturday, 01/05/2013 9:27:52 PM

Saturday, January 05, 2013 9:27:52 PM

Post# of 130743
EPGL TIMELINE w/Links. Full DD. Its important for everybody to know where EPGL Med came from and how it came to be at present time.
Where EPGL Med is right now, didn't happen overnight. If you are a current investor or one looking to invest, the following is a must read in it's entirety. All the DD you could possibly ask for is included. It will give you the confidence you need to weather the volatile days, that inevitably come in today'ss trading atmosphere.

After seeing how EPGL Med came to be, you will fully understand & realize the rarity of the situation that has made this investing opportunity the best you will ever come in contact with.

TIMELINE BEFORE EPGL RESTRUCTURING
History of MPDD, EP Global Communications, and the AJW Funds.

2005

Two renowned pain physicians, Dr. Norman Marcus and Dr. Hans Kraus (Dr. Kraus, President John F. Kennedy’s back doctor, helped found the field of sports and rehabilitative medicine.) and students at the Stephen's Institute of Technology, Jeckin Shah, Ryan Stellar (Currently a Biomed Engineer with EPGL Med) and Dan Silva form SPOC LLC (Stevens Proof of Concept), the company that first develops the MPDD in order to pinpoint the source of back pain. Eventually Digital Health Sciences acquired the license to all rights, title and interest in SPOC, LLC
SPOC LLC

March 18th, 2008
SPOC, LLC receives 501K clearance from the FDA for the Muscle Pain Detection Device. (MPDD)
FDA 501k Approval

Between 2009-2012
Dr. Norman Marcus and the Muscle Pain Detection Device, along with patient testimonials are featured on the Today Show, Fox News & Good Morning America. All are an absolute MUST WATCH!!
Today Show w/Dr. Marcus & MPDD
Fox News w/Dr. Marcus & MPDD
Good Morning America w/Dr. Marcus & MPDD

January 2010
Paper published by Corey Hunter, now EPGLmed's Medical Director, regarding the MPDD. To read the full article you have to purchase it. However, this link will take you to the page where you can view the abstract, etc, etc.
MPDD Published Research Paper

April 27th, 2010
EP Global Communication, a medical publishing company,(EPGL) and it's new Health Sciences Division, makes plans to assist Norman Marcus, MD, in increasing awareness of the efficacy and safety of the MPDD and therapies by featuring them in EP magazine, etc, etc. Thus begins EPGL's realtionship with the makers of the MPDD.
EPGL and the MPDD
However, nothing comes to be, as Corey Ribotsky of Nir Group, EPGL's main debt holder, pressures the company to enact massive dilution, due to the massive amount of convertible debt owed to them by EPGL thru it's PIPE financing, erasing all ways and means of the company obtaining the capital needed to enact it's awareness plan for the MPDD. EPGL will cease it's efforts as is tries for the next 2 years to try and convince Nir Group to renegotiate it's debt.

June 9th, 2010
Investigations of massive fraud by Corey Ribotsky and Nir Group, the main debt holder of EPGL, heat up.
Nir group Fraud

November 2nd, 2010
Filed with the USPTO in 2006, in Novemeber of 2010, The Muscle Pain Detection Device (MPDD) receives it's patent.
Patent # 7,826,900.
'Apparatus and method for diagnosing a source of muscular pain, wherein the apparatus includes a housing, an electrical signal generator mounted within the housing, and a pair of electrodes, one of which is mounted on one end of the housing and the other of which is mounted on an opposite end of the housing. The generator may include either an analog waveform generator or a digital signal processor. Each of the electrodes stimulates a muscle with an electrical signal generated by the generator. One of the electrodes has a relatively small contact area for targeting smaller muscles or muscle groups, while the other electrode has a relatively large contact area for targeting larger muscles or muscle groups. The apparatus is a self-contained, wireless unit and is highly maneuverable, which allows a user to quickly and easily diagnose a source of muscle pain.'
USPTO Patent Info for MPDD
Click on link, once on search page, enter patent # from above and search. All information about patent will be listed.

March 30th, 2011
As investigative pressure mounts, Corey Ribotsky decides to liquidate the AJW funds, where EPGL debt resides, assigning his own liquidator, pending the investigations being conducted by the SEC and FBI. He is then promptly sued by his investors. A judge then appoints PriceWaterhouseCooper to be the liquidator. Thus begins a year long legal battle by PwC to oust Ribotsky from having any say in the liquidation process of the AJW Fund.
PriceWaterhouseCoopers appointed Liquidator by Courts

September 28th, 2011
The Securities and Exchange Commission charged a Long Island-based investment adviser, Corey Ribotsky of Nir Group and their AJW Fund with defrauding investors in hedge funds investing in PIPE transactions and misappropriating more than $1 million in client assets for his personal use. EPGL currently is indebted to Corey Ribotsky through PIPE financing.
SEC Files Charges against Nir Group

February 2nd, 2012
Corey Ribotsky is finally forced out of NIR by Pricewaterhouse-Coopers, following the charges filed by the Securities and Exchange Commission.
PwC takes over liquidation of AJW Funds assets
PriceWaterhouseCoopers, with Ribotsky gone, can now start the liquidation process. First on it's list. EP Global Communications.

TIMELINE STARTING ONCE RESTRUCTURING OF EPGL IS INTRODUCED
A brand new Company and renewed life for the MPDD

March 28th, 2012:
EP Global Communications, Inc. Reaches Agreement With Major Debt Holders to Restructure and Become Medical Device Manufacturer and Marketing Company.
Deal Reached!

April 19th, 2012
EP Global Communications, Inc. Announces Details on Restructuring Plans and Upcoming Shareholder Meeting
Details

June 27th, 2012
EP Global Communications, Inc. Achieves Shareholder Approval for Restructuring and Signs Definitive Restructuring Agreement
Company Becomes Medical Device Manufacturer and Marketer
This is a MUST read

July 11th, 2012
EP Global Communications, Inc., Announces the Appointment of Corey W. Hunter M.D. as Company Medical Director and Chairman of Scientific Advisory Board. Respected Pain Physician Headed a Team of Scientists at NYU for Early Findings on the FDA Cleared MPDD Device. Will Now Lead Device to the U.S. and International Healthcare Markets.
All the toxic debt has now been eliminated and there will be no unscrupulous dumping of shares into the market as service to debt ever again. The restructuring partners will never consider such a financing arrangement in the future and will not allow that predicament to occur to the Company or its shareholders again. In contrast, the restructuring partners of the Company are committed to growing the Company and shareholder value significantly for the long term.
Corey Hunter, M.D. & Elimination of Toxic Debt

July 26th, 2012
EP Global Communications, Inc. Announces Friday July 27, 2012 as Effective Date for Approved Reverse Split
EP Global Communications, Inc., announces that FINRA has set Friday July 27, 2012 as the market effective date for the 10:1 reverse split of common outstanding shares. The Company shareholders previously approved the reverse split on June 8, 2012.
As a result, the Company will eliminate 100% of major debt and effectuate a new direction into the medical device manufacturing and marketing sector.
EPGL's Opening Day

August 21st, 2012
EPGL Launches Twitter account and begins to update shareholders regularly with tweets and Q&A sessions
Twitter Page

August 30th, 2012
EP Global Communications, Inc., Announces First Orders for MPDD Medical Device and the Addition of Eric Lee M.D. M.A. to Medical Team
First Revenues and Addition of Eric Lee, M.D.

September 5th, 2012

EPGL Med conducts it’s 1st Q&A session for investors via Twitter. They discuss the MPDD along with it’s potential, and company plans for the future, etc, etc.
Investor Q&A #1

September 24th, 2012
EP Global Communications, Inc. Lands One of the World's Leading Biomedical Engineers.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.
EPGL hires David T. Markus Ph.D

September 26th, 2012
EPGL Launches Website
EPGL Website

September 26th, 2012

EPGL Med conducts it’s 2nd Q&A session via Twitter for investors. They discuss fundamentals, management, the MPDD, etc, etc.
Twitter page detailing Investor Q&A #2

October 9th, 2012
Ryan M. Stellar M.E. B.E. joins Corey Hunter M.D., Eric Lee, M.D.M.A. and David T. Markus Ph.D. on the EPGL Team.
EPGL Team

October 17th, 2012
EPGL Med conducts 3rd Q&A session via Twitter with investors. They discuss new staff, sales goals, etc, etc.
Twitter page detailing Investor Q&A #3

November 28th, 2012
EP Global Communications, Inc. Releases Dramatically Improved Balance Sheet After Restructuring, Announces New Assets
For the First Time in Two Years, Company Begins to Report Again and Move Up OTC Tiers on the Way to Full SEC Reporting in 2013
EPGL Begins Reporting. Sheds 'No Info Status'

November 28th, 2012
EPGL is announcing today for the first time, it has acquired significant new assets other than the MPDD device rights, in the BioMEMS arena. BioMEMS will be a major focus for the Company going forward as previously announced.
BioMEMS devices are as important to the future of medicine as microprocessors were to the computer revolution at the end of the last century. BioMEMS is a science that includes more than simply finding biomedical applications for microelectromechanical systems devices. It represents an expansion into a host of new polymer materials, microfluidic physics, surface chemistries and their modification, 'soft' fabrication techniques, biocompatibility, and cost-effective solutions to biomedical problems. It brings together the creative talents of electrical, mechanical, optical, and chemical engineers, materials specialists, clinical laboratory scientists, and physicians. BioMEMS devices are the platform upon which nanomedicine will be delivered.
EPGL Enters bioMEMS Arena

November 28th, 2012

EPGL Med conducts it’s 4th Q&A session via Twitter with investors. They talk about entering the bioMEMS industry, getting to current status, etc, etc.
Investor Q&A #4

December 31st, 2012
EPGL Med files EP Global Communication's Annual Reports containing Income Statements and Balance Statements from 2010 and 2011
Balance Statement 2010
Income Statement 2010
Balance Statement 2011
Income Statement 2011

December 31st, 2012
EPGL Med files it's Articles of Incorporation
Articles of Incorporation

December 31st, 2012
EPGL Med files it's Bylaws
Bylaws

January 1st, 2013

EPGL Med files it's 2012 Annual Report, Initial Company Information and Disclosure Statement
*Highlights

Sharestructure
5,000,000,000 Authorized Common
4,668,000,000 Outstanding
499,161,167 Freely trading
The Company plans to manufacture, market and develop several new medical devices. Over the next 12 months, the company will seek strategic partners in equity finance, manufacturing and distribution to achieve these objectives.

The Company will not restructure again or propose any further reverse splits now or in the future. The Company believes it has more than adequate cash resources to see operations through the next 12 months.

Chronic back pain treatment in the United States alone is estimated to cost nearly $100 billion dollars annually. Utilizing recent Bureau of Labor Statistics data an estimate for the potential U.S. market for the MPDD is $2 billion and an additional $2.5 billion
globally, for a total potential market of $4.5 billion.

The Company projects that within 6 months of market launch, sales have the potential to exceed 2000 units per month worldwide and generating $10 million dollars per month.


For more highlights, read the damn report!!
Annual Report 2012

January 4th, 2013
EPGL files it's Attorney Letter to the OTC, finalizing the requirements needed to be uplisted from 'Limited Information' to 'Current Status'.
Attorney Letter

January 4th, 2013

EPGL Med conducts it’s 5th Q& with investors via Twitter. They reaffirms their goal of meeting all of the requirements of uplisting to the OTCQX U.S, the company’s share structure, etc, etc
Investor Q&A #5


January 4th, 2013

Via Twitter, EPGL Med selects a Singapore based firm for its Asia distribution. This, among other news will be detailed in January 25, 2013 announcements.
@EPGLMed




Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.